Unlock instant, AI-driven research and patent intelligence for your innovation.

Applications of amino methylene cyclohexane 1, 3-dione compound

A technology of compounds and uses, applied in the field of biomedicine

Inactive Publication Date: 2018-12-07
SUZHOU AUTOPHARM BIOPHARMACEUTICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on any regulators targeting LC3B, and the development of regulators of LC3B is very urgent for the treatment of related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of amino methylene cyclohexane 1, 3-dione compound
  • Applications of amino methylene cyclohexane 1, 3-dione compound
  • Applications of amino methylene cyclohexane 1, 3-dione compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Molecular level experiments of compounds or their salts targeting LC3B

[0048] By constructing a prokaryotic expression system to express and purify LC3B protein, a preliminary screening and verification platform was established by fluorescence polarization experiment, and the activity of the purchased and synthesized small compound library was determined.

[0049] Recombinant protein GST-LC3B (final concentration 180nM, SEQ ID NO:1) and N-terminal FITC-labeled peptide (SEQ ID NO:2, final concentration 18nM) were placed in FP buffer (50mM HEPES pH7.5, 0.1mg / mL BSA , 1 mM DTT), to which were added serially diluted compounds using FP buffer, and then the above mixture was incubated at 25° C. in the dark. Monitor the fluorescence polarization value (PerkinElmer Envision, emission wavelength 480nm; absorption wavelength 535nm), and calculate IC with GraphPadPrism 6.0 program 50 value.

[0050] The test results are shown in Table 1, wherein the IC of the compoun...

Embodiment 2

[0053] Example 2 Regulatory effect of compound or its salt on autophagy

[0054] Western blot detection of LC3-I / LC3-II protein

[0055] Hela cells were inoculated into 6-well plates, cultured overnight, treated with a certain concentration of compounds for 12 hours, and then starved for 24 hours with serum-free medium. Aspirate the culture medium, wash once with PBS, add SDS-PAGE and use 2× loading buffer to lyse the cells. The sample was boiled at 99°C for 10 minutes, separated by SDS-PAGE, and then detected by LC3B antibody (Novus) for LC3-I / LC3-II. The detection results are as follows: figure 2 As shown in A.

[0056] Depend on figure 2 A It can be seen that LC3-II accumulates with the prolongation of compound treatment time.

[0057] Immunofluorescence staining and fluorescence microscope photography

[0058] Hela cells were seeded on glass coverslips in a 6-well plate, cultured until the cells were in good condition, treated with a certain concentration of compoun...

Embodiment 3

[0060] Example 3 Inhibitory effects of compounds or their salts in combination with some marketed drugs on the proliferation of different types of tumor cells

[0061] Tumor cell lines: large B lymphoma cells (DB, Toledo, Pfeiffer, SU-DHL6, WSU-DLCL2, OCI-Ly19, SU-DHL2, SU-DHL8), mantle cell lymphoma cell lines (REC-1, Z- 138, Jeko-1, Maver-1), pancreatic cancer cell lines (AsPC-1, BxPC-3, MIAPaCa-2, Panc-3.014, CaPan-1, Panc-1), colon cancer cell line HCT116, non-small cell Lung cancer cell lines (PC9, HCC827, NCI-H1975) and multiple myeloma cell lines (H929, KMS26, RPMI-8226).

[0062] Listed drugs used in combination: ibrutinib, imatinib, gemcitabine, erlotinib, pemetrexed disodium, AZD3759 and lenalidomide.

[0063] Experimental method: use complete medium containing 10% FBS, after cell counting, inoculate ~10000 cells / 100 μL per well in 96-well plate, at the same time give the marketed drug and compound 38 treatment, the drug is diluted in a concentration gradient of 1:3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to applications of an amino methylene cyclohexane 1, 3-dione compound, and relates to applications of a compound represented by formula I, or a pharmaceutically acceptable salt of the compound, or a composition of the compound with other medicines in preparation of medicines used for adjusting cell autophagy, treating cell autophagy, and especially mammal ATG8 homologous protein related diseases.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a class of aminomethylenecyclohexane 1,3-diketone compounds or salts thereof used in the preparation of drugs for treating diseases related to autophagy, especially mammalian ATG8 homologous protein the use of. Background technique [0002] Autophagy is an intracellular degradation pathway, which is the process of transporting damaged or dysfunctional proteins and organelles in cells to lysosomes for digestion and degradation. In biological evolution, autophagy is a conserved process, which exists from yeast to plant cells to mammals. [0003] Existing studies have shown that autophagy plays an important role in maintaining physiological functions such as providing nutrition during starvation, clearing cell contents, and antigen presentation, and plays an important role in cancer, cardiovascular disease, autoimmune disease, neurodegenerative Diseases, hypertension, bone cells and bon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K31/495A61K31/4402A61K31/4725A61K31/341A61K31/415A61K31/13A61K31/17A61K31/18A61K31/136A61K31/5375A61K31/44A61K31/496A61K31/4525A61K31/4166A61P35/00A61P35/02A61P37/02A61P25/28A61P9/12A61P9/00A61P19/08A61P13/12A61P9/10A61P27/02A61P11/06A61P31/00
CPCA61K31/13A61K31/136A61K31/137A61K31/17A61K31/18A61K31/341A61K31/415A61K31/4166A61K31/44A61K31/4402A61K31/4525A61K31/4725A61K31/495A61K31/496A61K31/5375A61P9/00A61P9/10A61P9/12A61P11/06A61P13/12A61P19/08A61P25/28A61P27/02A61P31/00A61P35/00A61P35/02A61P37/02A61K45/06A61K31/519A61K31/7068A61K31/506A61K31/517A61K31/454A61P1/00A61K2300/00A61K31/133A61K31/135A61K31/497
Inventor 罗成乐立艳万伟张元元蒋华良陈凯先
Owner SUZHOU AUTOPHARM BIOPHARMACEUTICAL CO LTD